Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fosun Pharma
Biotech
Fosun pays $60M for option on AriBio’s phase 3 Alzheimer’s asset
Fosun Pharma secured the chance to expand its rights to the asset in exchange for a further $80 million.
Nick Paul Taylor
May 13, 2026 9:15am
Insilico agrees to $66M deal to split rights for NLRP3 inhibitor
Jan 21, 2026 7:05am
VC Aditum launches new biotech for foray with Fosun
Dec 19, 2025 11:25am
Expedition resupplies for ph. 2 COPD voyage with $165M series A
Oct 9, 2025 9:50am
Fosun rises again, beaming up 3rd biotech deal in 3 weeks
Aug 29, 2025 10:05am
Sitala seals $670M deal for Fosun immune disease drug
Aug 26, 2025 2:44pm
